Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Zymeworks drops clinical-stage TCE over benefit-risk profile
Zymeworks is abandoning a T-cell engager after assessing the cancer drug’s benefit-risk profile in a phase 1 study.
James Waldron
Sep 2, 2025 8:10am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
German cancer antibody biotech eyes SPAC as route to Nasdaq
Apr 23, 2025 6:09am
